Articles From: Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013 to Exelon Makes Dow Jones Sustainability Index for Eighth Consecutive Year; Only U.S. Utility on CDP Global Indexes for Climate Performance and Disclosure


2013/9/28
Exelixis, Inc. (NASDAQ:EXEL) today announced updated results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib (GDC-0973/XL518) in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAF V600 mutation.
Sign-up for Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013 investment picks
2014/1/23
Exelixis, Inc. (Nasdaq: EXEL) today announced the pricing of its overnight underwritten public offering of 10,000,000 shares of newly issued common stock at a price to the public of $8.00 per share.
Sign-up for Exelixis Announces Pricing of Overnight Offering of 10,000,000 Shares of Common Stock investment picks
2013/8/6
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended June 30, 2013.
Sign-up for Exelixis Announces Second Quarter 2013 Financial Results investment picks
2013/10/30
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended September 30, 2013.
Sign-up for Exelixis Announces Third Quarter 2013 Financial Results investment picks
2013/11/26
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Sign-up for Exelixis Announces Webcast of December 3 Presentation at the 25th Annual Piper Jaffray Healthcare Conference investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Sign-up for Exelixis Announces Webcast of January 15 Presentation at the J.P. Morgan 32nd Annual Healthcare Conference investment picks
2014/1/31
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Sign-up for Exelixis Announces Webcasts of Investor Conference Presentations in February investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Sign-up for Exelixis Announces Webcasts of Investor Conference Presentations in September investment picks
2014/2/12
Exelixis, Inc. (NASDAQ: EXEL) today announced the appointment of Jeffrey J.
Sign-up for Exelixis Appoints Executive Vice President and General Counsel investment picks
2013/9/10
Exelixis, Inc. (NASDAQ:EXEL) today announced that it has initiated CELESTIAL, a phase 3 pivotal trial comparing cabozantinib with placebo in patients with advanced hepatocellular carcinoma (HCC) who have previously been treated with sorafenib.
Sign-up for Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib in Patients With Advanced Hepatocellular Carcinoma investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that it has initiated a phase 2 clinical trial comparing cabozantinib plus abiraterone and prednisone (abiraterone/prednisone) versus abiraterone/prednisone in patients with castration-resistant prostate cancer (CRPC) who have bone metastases and have not been previously treated with chemotherapy.
Sign-up for Exelixis Initiates Randomized Phase 2 Clinical Trial of Cabozantinib Plus Abiraterone in Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer investment picks
2014/1/22
Exelixis, Inc. (Nasdaq: EXEL) today announced that it plans to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an overnight underwritten public offering.
Sign-up for Exelixis Launches Proposed Overnight Public Offering of Common Stock investment picks
2014/3/25
Exelixis, Inc. (NASDAQ:EXEL) announced that the Independent Data Monitoring Committee (IDMC) notified the company today that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis.
Sign-up for Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer investment picks
2014/3/25
Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Commission has approved COMETRIQ® (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). The European Commission granted conditional marketing authorization following a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) issued in December 2013.
Sign-up for Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma investment picks
2013/10/30
By Tess Stynes Exelon Corp.'s (EXC) third-quarter earnings surged as the nuclear-power producer benefited from positive hedging impacts and lower costs.
Sign-up for Exelon 3rd-Quarter Profit Soars on Positive Hedging Impacts, Lower Costs investment picks
2014/3/19
Exelon Corporation today announced it has reached an agreement to purchase ETC ProLiance Energy, an Indianapolis-based supplier of natural gas to commercial and industrial customers, plus power generators and utilities, over 2,500 customer facilities.
Sign-up for Exelon Announces Acquisition of ETC ProLiance Energy investment picks
Exelon Corporation (NYSE: EXC) announced second quarter 2013 consolidated earnings as follows: “Exelon delivered earnings within its guidance range and continued to operate well this quarter, both in the generation and utility businesses,” said Christopher M.
Sign-up for Exelon Announces Second Quarter 2013 Results, Reaffirms Full-Year Guidance investment picks
2014/2/6
Exelon Corporation (NYSE: EXC) announced fourth quarter 2013 and full year consolidated earnings as follows:             Full Year   Fourth Quarter     2013   2012   2013   2012 Adjusted (non-GAAP)
Sign-up for Exelon Announces Solid Fourth Quarter 2013 Results, Provides 2014 Earnings Expectation investment picks
Exelon Corporation (NYSE: EXC) announced third quarter 2013 consolidated earnings as follows:         Third Quarter     2013   2012 Adjusted (non-GAAP) Operating Results:   Net Income ($ millions) $667 $658
Sign-up for Exelon Announces Solid Third Quarter 2013 Results, Narrows Full Year Earnings Expectation investment picks
2014/4/9
In a keynote address to the 29th Annual Platts Global Power Markets Conference, Exelon Generation President and CEO Kenneth W.
Sign-up for Exelon Calls for Energy Policy and Market Reforms to Ensure Clean, Reliable Energy Supply investment picks
2013/10/14
The Exelon family of companies is helping to educate Illinoisans about the need for a strong energy workforce and encourage them to consider careers in the energy industry as part of the state’s inaugural Careers in Energy Week.
Sign-up for Exelon Celebrates “Careers in Energy Week” in Illinois with Events Focused on Working in the Energy Field investment picks
2013/10/22
The Board of Directors of Exelon Corporation declared a regular quarterly dividend of $0.31 per share on Exelon’s common stock.
Sign-up for Exelon Corporation Declares Dividend investment picks
2014/1/28
The Board of Directors of Exelon Corporation declared a regular quarterly dividend of $0.31 per share on Exelon’s common stock.
Sign-up for Exelon Corporation Declares Dividend investment picks
2013/8/9
In an effort to help young Army soldiers get good jobs after they complete their military service, Exelon Corporation and the U.S. Army yesterday signed an agreement to partner in the Army Partnership for Youth Success (PaYS) program at a ceremony at the Pritzker Military Library.
Sign-up for Exelon Corporation, U.S. Army Partner to Create Job Opportunities for Veterans investment picks
2014/2/4
http://media.marketwire.com/attachments/201312/209612_marketwire_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1086948&ProfileId=051205&sourceType=1 SUGAR LAND, TX --
Sign-up for Exelon Corporation's Perryman Peaking Plant in Maryland to Add 120-Megawatt Unit, an Industrial Info News Alert investment picks
2014/4/7
Employees from across the Exelon family of companies will observe National Volunteer Week (April 6-12) by participating in more than 150 employee-led service projects in the communities Exelon serves, from cleaning up parks and other public spaces to serving meals to people struggling with poverty to mentoring at-risk students.
Sign-up for Exelon Employees Observe National Volunteer Week by Leading More Than 150 Community Service Projects investment picks
Remotely piloted robots mingled with hundreds of employees strolling the halls of the Pier 5 Hotel yesterday as Exelon Corporation launched the first in a series of Innovation Expos aimed at bringing together employees and outside experts to explore innovative solutions to complex business problems.
Sign-up for Exelon Holds First Innovation Expo as Part of Emerging Technology Initiative investment picks
As part of its continuing efforts to promote strong neighborhoods in the communities where it operates, Exelon Corporation has joined the City of Baltimore’s Live Near Your Work program, which provides up to $5,000 to employees who help strengthen Baltimore’s urban areas by purchasing a home in the city.
Sign-up for Exelon Joins Program to Expand Baltimore City Home Ownership investment picks
The U.S. Court of Federal Claims ruled against Exelon Corp.
Sign-up for Exelon Loses Tax Dispute, Says Decision Won't Affect Earnings -Bloomberg investment picks
Two separate global authorities on corporate sustainability – the Dow Jones Sustainability Indices (DJSI) and CDP – have recognized Exelon for its sustainability performance and climate change performance and reporting.
Sign-up for Exelon Makes Dow Jones Sustainability Index for Eighth Consecutive Year; Only U.S. Utility on CDP Global Indexes for Climate Performance and Disclosure investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013 to Exelon Makes Dow Jones Sustainability Index for Eighth Consecutive Year; Only U.S. Utility on CDP Global Indexes for Climate Performance and Disclosure
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity